Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Shah, N. N., Coombs, C. C., Ujjani, C. S., Fakhri, B., Cheah, C. Y., Patel, M. R., Alencar, A. J., Cohen, J. B., Gerson, J. N., … Jurczak, W. (2023). Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 389(1), 33–44. https://doi.org/10.1056/nejmoa2300696

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319–332. https://doi.org/10.1056/nejmoa2211582

Lipsky, A. H., & Lamanna, N. (2022). Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia. Cancer, 129(1), 18–31. Portico. https://doi.org/10.1002/cncr.34510

Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D’Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, J. Q., Jiang, Y., Lefebure, M., … Kater, A. P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140(8), 839–850. https://doi.org/10.1182/blood.2021015014

Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., … Laetsch, T. W. (2022). Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 40(9), 945–955. https://doi.org/10.1200/jco.20.03585

Ma, X.-Y., Zhao, M., Li, Y.-D., Chen, Y., Wei, L., & Chen, Z.-S. (2022). Research progress in overcoming ibrutinib drug resistance. Drugs of Today, 58(2), 85–94. https://doi.org/10.1358/dot.2022.58.2.3360405

Gregory, G. P., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F. J., Klein, A., Pagel, J. M., Rybka, W., Yee, A. J., Mohrbacher, A., Huang, M., Farooqui, M., Marinello, P., & Quach, H. (2022). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 6(4), 1232–1242. https://doi.org/10.1182/bloodadvances.2021005872

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Stonesifer, C. J., Trager, M. H., Magro, C. M., & Geskin, L. J. (2021). CD8+ Lymphogranulomatous Dermatitis as a Manifestation of Malignancy-Associated Immunodeficiency: Rethinking Paraneoplastic Granulomas. The American Journal of Dermatopathology, 43(12), e222–e226. https://doi.org/10.1097/dad.0000000000002068

Herrera, A. F., Ahn, K. W., Litovich, C., Chen, Y., Assal, A., Bashir, Q., Bayer, R.-L., Coleman, M., DeFilipp, Z., Farhadfar, N., Greenwood, M., Hahn, T., Horwitz, M., Jacobson, C., Jaglowski, S., Lachance, S., Langston, A., Mattar, B., Maziarz, R. T., … Hamadani, M. (2021). Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome. Blood Advances, 5(18), 3528–3539. https://doi.org/10.1182/bloodadvances.2021004865